Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded to “Hold” by StockNews.com

Cyclacel Pharmaceuticals (NASDAQ:CYCC) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

Several other equities research analysts have also commented on CYCC. Roth Mkm boosted their price objective on shares of Cyclacel Pharmaceuticals from $16.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, December 19th. Brookline Capital Management lowered shares of Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th.

Cyclacel Pharmaceuticals Trading Up 4.2 %

CYCC stock opened at $2.00 on Tuesday. The company has a market cap of $1.68 million, a price-to-earnings ratio of -0.07 and a beta of 0.56. The firm has a 50 day moving average of $2.43 and a 200-day moving average of $4.27. Cyclacel Pharmaceuticals has a 12-month low of $1.82 and a 12-month high of $13.20.

Institutional Trading of Cyclacel Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. HRT Financial LP acquired a new position in shares of Cyclacel Pharmaceuticals during the 4th quarter valued at about $27,000. Virtu Financial LLC acquired a new position in Cyclacel Pharmaceuticals during the second quarter worth approximately $33,000. Renaissance Technologies LLC purchased a new position in Cyclacel Pharmaceuticals during the second quarter worth approximately $68,000. Two Sigma Investments LP acquired a new position in shares of Cyclacel Pharmaceuticals in the 3rd quarter valued at $98,000. Finally, Millennium Management LLC acquired a new position in shares of Cyclacel Pharmaceuticals in the 2nd quarter valued at $113,000. 23.58% of the stock is owned by institutional investors and hedge funds.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.